Radient Pharmaceuticals Corporation fka RXPC

[lakeshore555]

dcspka you said:

"Lakeshore: Why would William Gartner continue pursuing RXPC if he did not pay the full $280,000 as per terms of the agreement? "

Answer: William Gartner is not pursuing RXPC. He is pursuing FUNDING. In his AZBio sales pitch and on Fundable, he pursued FUNDING. When/If he gets funding, he will then pursue a license for DR-70, or he will wait until after June 3rd, after which he won't need that license. In NO scenario would he care whether RXPC merges with or is taken over by another entity. A Radient merger or takeover doesn't help Gartner or GCDx in any way.

If what you and wolfie say is true -- Gartner already has the license for DR-70 and Gartner filed his own patent application for his LC test -- the best thing for Gartner and GCDx would be for RXPC to go bankrupt and disappear. Gartner already got the one thing he wanted from RXPC, according to you.

Incidentally, it looks like Dignyte/eWellness is a go:

https://www.sec.gov/Archives/edgar/data/1550020/000149315214001111/form8k.htm

Looks to me like MacLellan has abandoned Radient and is moving on to other business ventures. First KwicKans, then his real estate business in Florida, now eWellness. Meanwhile, Radient sits idle.